AbbVie
Executive Summary
There appears to be a data error - AbbVie is a major US pharmaceutical company headquartered in North Chicago, not a Chinese entity. AbbVie is a Fortune 500 company spun off from Abbott in 2013, known for blockbuster drugs like Humira and Skyrizi. As a US-domiciled company, AbbVie has no BIOSECURE Act exposure and would typically be an acquirer rather than target in BD transactions. This profile request may have incorrect entity identification.
Structure: If this were actually a Chinese entity, more information would be needed to assess corporate structure. However, AbbVie Inc. is a standard US Delaware corporation with straightforward public company governance. No VIE structure or complex holding company arrangements typical of Chinese pharma entities.
Ownership & Shareholder Structure
Everest Medicines → AbbVie
Everest licensed multiple AbbVie assets for Greater China development.
Gracell Biotechnologies → AbbVie
AbbVie acquired Gracell for $1.2B (Jan 2024) for BCMA/CD19 dual CAR-T platform.
NovaBridge Biosciences → AbbVie
NovaBridge (formerly I-Mab) lemzoparlimab collaboration with AbbVie.
BIOSECURE Risk
AbbVie is a US-headquartered, NYSE-listed pharmaceutical company with no Chinese ownership or control
Mitigation: Not applicable - no BIOSECURE risk as US entity
BD Intelligence
Therapeutic Areas:
Recent Deals: Major acquirer with deals including Pharmacyclics ($21B), Allergan ($63B), and numerous licensing agreements
Approach: Verify entity identification - if seeking partnership with AbbVie, approach through established BD channels as they are active acquirers and licensors
Red Flags
- ⚠Entity identification mismatch - AbbVie is US company, not Chinese
- ⚠No subsidiary or key people data suggests incomplete intelligence
- ⚠Potential confusion in target identification for BD evaluation
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 10
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.